Compare JJSF & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | MPLT |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | 1800 | 133 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1995 | N/A |
| Metric | JJSF | MPLT |
|---|---|---|
| Price | $75.92 | $37.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $140.00 | $32.67 |
| AVG Volume (30 Days) | 231.6K | ★ 437.1K |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | $584.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $12.24 |
| 52 Week High | $129.24 | $37.61 |
| Indicator | JJSF | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 69.84 |
| Support Level | $72.93 | $26.20 |
| Resistance Level | $78.42 | N/A |
| Average True Range (ATR) | 2.52 | 2.49 |
| MACD | 0.13 | 0.84 |
| Stochastic Oscillator | 44.32 | 95.22 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.